These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. Docherty KF; Ogunniyi MO; Anand IS; Desai AS; Diez M; Howlett JG; Nicolau JC; O'Meara E; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Lindholm D; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV JACC Heart Fail; 2022 Jan; 10(1):52-64. PubMed ID: 34969498 [TBL] [Abstract][Full Text] [Related]
8. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593 [TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108 [TBL] [Abstract][Full Text] [Related]
10. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447 [TBL] [Abstract][Full Text] [Related]
11. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. Butt JH; Dewan P; DeFilippis EM; Biering-Sørensen T; Docherty KF; Jhund PS; Kosiborod MN; Martinez FA; Bengtsson O; Johansen ND; Langkilde AM; Sjöstrand M; Vaduganathan M; Solomon SD; Sabatine MS; Køber L; Fiuzat M; McMurray JJV JACC Heart Fail; 2022 Aug; 10(8):543-555. PubMed ID: 35902157 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328 [TBL] [Abstract][Full Text] [Related]
13. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831 [TBL] [Abstract][Full Text] [Related]
15. Regional Handling and Prognostic Performance of Circulating Insulin-Like Growth Factor Binding Protein-7 in Heart Failure. Tan ESJ; Chan SP; Choi YC; Pemberton CJ; Troughton R; Poppe K; Lund M; Devlin G; Doughty RN; Richards AM JACC Heart Fail; 2023 Jun; 11(6):662-674. PubMed ID: 37286261 [TBL] [Abstract][Full Text] [Related]
16. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Serenelli M; Böhm M; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; DeMets DL; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Chiang CE; Chopra VK; de Boer RA; Diez M; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Verma S; Docherty KF; Jhund PS; McMurray JJV Eur Heart J; 2020 Sep; 41(36):3402-3418. PubMed ID: 32820334 [TBL] [Abstract][Full Text] [Related]
17. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Dewan P; Docherty KF; Bengtsson O; de Boer RA; Desai AS; Drozdz J; Hawkins NM; Inzucchi SE; Kitakaze M; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Verma S; Jhund PS; McMurray JJV Eur J Heart Fail; 2021 Apr; 23(4):632-643. PubMed ID: 33368858 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288 [TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498 [TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]